Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dimensionality-driven optical and electronic evolution of naphthalenediimide-templated hybrid metal oxides.

Chemical science·2026
Same author

Early maturation of host antimicrobial peptide defences is associated with host-pathogen coexistence.

Nature chemical biology·2026
Same author

The Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study.

Open forum infectious diseases·2026
Same author

Long-Lived Photochromism in a Crystalline Hybrid Naphthalenediimide-Polyoxovanadate System.

Inorganic chemistry·2026
Same author

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.

Trials·2026
Same author

Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026

Related Experiment Video

Updated: Jul 6, 2026

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing
05:50

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing

Published on: January 20, 2026

A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer.

Aristides D Tagalakis1, Robin J McAnulty, James Devaney

  • 1Wolfson Centre for Gene Therapy of Childhood Disease, University College London Institute of Child Health, London,UK.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 5, 2008
PubMed
Summary

New synthetic vectors show promise for cystic fibrosis (CF) gene therapy. LED-1 effectively targets airway cells and allows repeated dosing, unlike other tested formulations.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing
05:50

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing

Published on: January 20, 2026

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Area of Science:

  • Gene Therapy
  • Nanomedicine
  • Respiratory Medicine

Background:

  • Cystic Fibrosis (CF) gene therapy requires vectors that specifically target airway epithelial cells.
  • Vectors must be non-immunogenic for repeated administration and avoid transfection of alveolar cells or macrophages.
  • Existing vectors like GL67 and polyethylenimine (PEI) have limitations in efficiency, toxicity, or immunogenicity.

Purpose of the Study:

  • To compare the efficacy and safety of synthetic vector formulations for CF gene therapy.
  • To identify vectors suitable for airway epithelial cell targeting and repeated delivery.
  • To evaluate vector stability for nebulization, a key delivery method for CF.

Main Methods:

  • Comparison of GL67, PEI (22 and 25 kDa), and two novel receptor-targeted nanocomplexes (RTNs): LED-1 (peptide-based) and LED-2 (lipid-based).
  • Assessment of transfection efficiency in airway and alveolar epithelial cells in vivo.
  • Evaluation of toxicity and immune response following single and repeated dosing.
  • Testing of vector stability after nebulization.

Main Results:

  • LED-1 demonstrated efficient airway epithelial cell transfection and maintained efficacy upon repeated dosing.
  • LED-2 and GL67 preferentially transfected alveolar cells.
  • PEI showed high airway transfection efficiency but significant toxicity and reduced efficacy on repeat dosing.
  • LED-1 formulations were stable following nebulization.

Conclusions:

  • LED-1 is the only formulation meeting all criteria for an ideal CF gene therapy vector, including airway targeting, non-immunogenicity, and stability for nebulization.
  • GL67 and LED-2 may be suitable for other respiratory diseases.
  • Further development of PEI requires addressing its toxicity issues.